Tumour-initiating cell-specific MIR-1246 and MIR-1290 expression converge to promote non-small cell lung cancer progression

Nature Communications

Volumn 7, Issue , 2016, Pages

  Zhang, Wen Cai ^a,j   Chin, Tan Min ^b,c   Yang, Henry ^b   Nga, Min En ^d   Lunny, Declan Patrick ^e   Lim, Edwin Kok Hao ^a   Sun, Li Li ^a   Pang, Yin Huei ^d   Leow, Yi Ning ^a   Malusay, Shanneen Rossellini Y ^a   Lim, Priscilla Xin Hui ^a   Lee, Jeravan Zili ^a   Tan, Benedict Jian Wei ^a   Ng, Shyh Chang ^a   Lim, Elaine Hsuen ^f,g   Lim, Wan Teck ^g   Tan, Daniel Shao Weng ^a,g   Tan, Eng Huat ^g   Tai, Bee Choo ^h   Soo, Ross Andrew ^b,c   Tam, Wai Leong ^a,b,i   Lim, Bing ^a,k   more..

^a GENOME INSTITUTE OF SINGAPORE   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Cancer Institute   (Singapore)

^d NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^e INSTITUTE OF MEDICAL BIOLOGY   (Singapore)

^f TAN TOCK SENG HOSPITAL   (Singapore)

^g DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^h NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

ⁱ NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^j HARVARD MEDICAL SCHOOL   (United States)

^k Merck Sharp and Dohme Translational Medicine Research Centre   (Singapore)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 1246; MICRORNA 1290; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GEFITINIB; HYDROXYCHLOROQUINE; LOCKED NUCLEIC ACID; MIRN1246 MICRORNA, HUMAN; MIRN1290 MICRORNA, HUMAN; OLIGONUCLEOTIDE; QUINAZOLINE DERIVATIVE;

BIOMARKER; CANCER; CELLS AND CELL COMPONENTS; CHEMOTHERAPY; GENE EXPRESSION; HETEROGENEITY; PHENOTYPE; RESPIRATORY DISEASE; RNA; TUMOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CARCINOGENICITY; CELLS BY BODY ANATOMY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; METASTASIS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; TREATMENT RESPONSE; TUMOR INITIATING CELL; A-549 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; DISEASE EXACERBATION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; LUNG TUMOR; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR VOLUME;

A549 CELLS; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEK293 CELLS; HUMANS; HYDROXYCHLOROQUINE; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MICE; MICRORNAS; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDES; QUINAZOLINES; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84975887156     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms11702     Document Type: Article

References (66)

1. Herbst, R. S., Heymach, J. V. & Lippman, S. M. Lung cancer. N. Engl. J. Med. 359, 1367-1380 (2008).
2. Chen, Z., Fillmore, C. M., Hammerman, P. S., Kim, C. F. & Wong, K. K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat. Rev. Cancer 14, 535-546 (2014).
3. Nguyen, L. V., Vanner, R., Dirks, P. & Eaves, C. J. Cancer stem cells: an evolving concept. Nat. Rev. Cancer 12, 133-143 (2012).
4. Chen, J. et al. A restricted cell population propagates glioblastoma growth after chemotherapy. Nature 488, 522-526 (2012).
5. Vanner, R. J. et al. Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. Cancer Cell 26, 33-47 (2014).
6. Tam, W. L. & Ng, H. H. Sox2: masterminding the root of cancer. Cancer Cell 26, 3-5 (2014).
7. Tam, W. L. et al. Protein kinase C alpha is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell 24, 347-364 (2013).
8. Gupta, P. B. et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 138, 645-659 (2009).
9. Sun, X. et al. MicroRNAs and cancer stem cells: the sword and the shield. Oncogene 33, 4967-4977 (2014).
10. Lujambio, A. & Lowe, S. W. The microcosmos of cancer. Nature 482, 347-355 (2012).
11. Berindan-Neagoe, I., Monroig Pdel, C., Pasculli, B. & Calin, G. A. MicroRNAome genome: a treasure for cancer diagnosis and therapy. CA. Cancer J. Clin. 64, 311-336 (2014).
12. Kasinski, A. L. & Slack, F. J. Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat. Rev. Cancer 11, 849-864 (2011).
13. Cheng, C. J. et al. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 518, 107-110 (2015).
14. Lieberman, J. et al. Noncoding RNAs and cancer. Cell 153, 9-10 (2013).
15. Hayes, J., Peruzzi, P. P. & Lawler, S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends. Mol. Med. 20, 460-469 (2014).
16. Lu, J. et al. MicroRNA expression profiles classify human cancers. Nature 435, 834-838 (2005).
17. Mendell, J. T. miRiad roles for the miR-17-92 cluster in development and disease. Cell 133, 217-222 (2008).
18. Johnson, S. M. et al. RAS is regulated by the let-7 microRNA family. Cell 120, 635-647 (2005).
19. Viswanathan, S. R. et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat. Genet. 41, 843-848 (2009).
20. Hwang, W. L. et al. MicroRNA-146a directs the symmetric division of Snail-dominant colorectal cancer stem cells. Nat. Cell. Biol. 16, 268-280 (2014).
21. Song, S. J. et al. MicroRNA-Antagonism regulates breast cancer stemness and metastasis via TET-family-dependent chromatin remodeling. Cell 154, 311-324 (2013).
22. Song, S. J. et al. The oncogenic microRNA miR-22 targets the TET2 tumor suppressor to promote hematopoietic stem cell self-renewal and transformation. Cell Stem Cell 13, 87-101 (2013).
23. Yu, F. et al. let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131, 1109-1123 (2007).
24. Chen, X. et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell. Res. 18, 997-1006 (2008).
25. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl Acad. Sci. USA 105, 10513-10518 (2008).
26. Schwarzenbach, H., Nishida, N., Calin, G. A. & Pantel, K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat. Rev. Clin. Oncol. 11, 145-156 (2014).
27. Zhang, W. C. et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148, 259-272 (2012).
28. Takamizawa, J. et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res. 64, 3753-3756 (2004).
29. Zhu, X. et al. Studies on microRNAs that are correlated with the cancer stem cells in chronic myeloid leukemia. Mol. Cell. Biochem. 390, 75-84 (2014).
30. Fabbri, M. et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc. Natl Acad. Sci. USA 104, 15805-15810 (2007).
31. Hayashita, Y. et al. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res. 65, 9628-9632 (2005).
32. Lu, Y., Thomson, J. M., Wong, H. Y., Hammond, S. M. & Hogan, B. L. Transgenic over-expression of the microRNA miR-17-92 cluster promotes proliferation and inhibits differentiation of lung epithelial progenitor cells. Dev. Biol. 310, 442-453 (2007).
33. Ventura, A. et al. Targeted deletion reveals essential and overlapping functions of the miR-17 through 92 family of miRNA clusters. Cell 132, 875-886 (2008).
34. Liu, X. H. et al. MicroRNA-196a promotes non-small cell lung cancer cell proliferation and invasion through targeting HOXA5. BMC Cancer 12, 348 (2012).
35. Ma, L. et al. miR-9, a MYC/MYCN-Activated microRNA, regulates E-cadherin and cancer metastasis. Nat. Cell. Biol. 12, 247-256 (2010).
36. Ma, S. et al. miR-130b Promotes CD133(+) liver tumor-initiating cell growth and self-renewal via tumor protein 53-induced nuclear protein 1. Cell Stem Cell 7, 694-707 (2010).
37. Li, F., Tiede, B., Massague, J. & Kang, Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell. Res. 17, 3-14 (2007).
38. Valent, P. et al. Cancer stem cell definitions and terminology: the devil is in the details. Nat. Rev. Cancer. 12, 767-775 (2012).
39. Boiko, A. D. et al. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature 466, 133-137 (2010).
40. Taylor, D. D. & Gercel-Taylor, C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 110, 13-21 (2008).
41. Resnick, K. E. et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol. Oncol. 112, 55-59 (2009).
42. Leidinger, P. et al. High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer 10, 262 (2010).
43. Elmen, J. et al. LNA-mediated microRNA silencing in non-human primates. Nature 452, 896-899 (2008).
44. Meric-Bernstam, F. & Mills, G. B. Overcoming implementation challenges of personalized cancer therapy. Nat. Rev. Clin. Oncol. 9, 542-548 (2012).
45. Liang, G. Y. et al. Expression of metallothionein and Nrf2 pathway genes in lung cancer and cancer-surrounding tissues. World J. Surg. Oncol. 11, 199 (2013).
46. Kanda, M. et al. Detection of metallothionein 1G as a methylated tumor suppressor gene in human hepatocellular carcinoma using a novel method of double combination array analysis. Int. J. Oncol. 35, 477-483 (2009).
47. Satoh, M. Toxicological significance of metallothionein on environmental harmful factors: verification and suggestions from a metallothionein-I/II null mouse model study. Nihon Eiseigaku Zasshi 59, 317-325 (2004).
48. Suzuki, J. S. et al. Metallothionein deficiency enhances skin carcinogenesis induced by 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol-13-Acetate in metallothionein-null mice. Carcinogenesis 24, 1123-1132 (2003).
49. Werynska, B. et al. Expression of metallothionein-III in patients with non-small cell lung cancer. Anticancer Res. 33, 965-974 (2013).
50. Ioachim, E. E. et al. Prognostic evaluation of metallothionein expression in human colorectal neoplasms. J. Clin. Pathol. 52, 876-879 (1999).
51. Stahlhut, C. & Slack, F. J. Combinatorial action of microRNAs let-7 and miR-34 effectively synergizes with erlotinib to suppress non-small cell lung cancer cell proliferation. Cell Cycle 14, 2171-2180 (2015).
52. Kasinski, A. L. et al. A combinatorial microRNA therapeutics approach to suppressing non-small cell lung cancer. Oncogene 34, 3547-3555 (2014).
53. Xue, W. et al. Small RNA combination therapy for lung cancer. Proc. Natl Acad. Sci. USA 111, E3553-E3561 (2014).
54. Shao, D. D. et al. KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 158, 171-184 (2014).
55. Todaro, M. et al. CD44v6 is a marker of constitutive and reprogrammed cancer stem cells driving colon cancer metastasis. Cell Stem Cell 14, 342-356 (2014).
56. Dieter, S. M. et al. Distinct types of tumor-initiating cells form human colon cancer tumors and metastases. Cell Stem Cell 9, 357-365 (2011).
57. Boumahdi, S. et al. SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinoma. Nature 511, 246-250 (2014).
58. Zhu, Z. et al. Targeting self-renewal in high-grade brain tumors leads to loss of brain tumor stem cells and prolonged survival. Cell Stem Cell 15, 185-198 (2014).
59. Chan, C. H. et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 154, 556-568 (2013).
60. Wang, Y., Liu, Y., Malek, S. N. & Zheng, P. Targeting HIF1alpha eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 8, 399-411 (2011).
61. Arriaga, J. M., Greco, A., Mordoh, J. & Bianchini, M. Metallothionein 1G and zinc sensitize human colorectal cancer cells to chemotherapy. Mol. Cancer Ther. 13, 1369-1381 (2014).
62. Arriaga, J. M. et al. Metallothionein expression in colorectal cancer: relevance of different isoforms for tumor progression and patient survival. Hum. Pathol. 43, 197-208 (2012).
63. Ferrario, C. et al. Metallothionein 1G acts as an oncosupressor in papillary thyroid carcinoma. Lab. Invest. 88, 474-481 (2008).
64. Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer. 45, 228-247 (2009).
65. Chua, S. W. et al. A novel normalization method for effective removal of systematic variation in microarray data. Nucleic Acids Res. 34, e38 (2006).
66. Geissmann, Q. OpenCFU, a new free and open-source software to count cell colonies and other circular objects. PLoS ONE 8, e54072 (2013).